Indeed, similarly to previous reports in breast cancer and gastric cancer progressing on HER2-targeted therapy, the single most common resistance mechanism in this cohort was loss of HER2 amplification, which has been correlated with lack of response to later-line HER2-directed therapies. This evidence concerns the gene ERBB2 and breast carcinoma.